Regen BioPharma a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. , announced today filing of an Investigational New Drug application with the FDA to initiate clinical trials assessing the company's HemaXellerate I is a patient-specific composition of cells that have previously been demonstrated to repair damaged bone marrow and ... (more)
http://www.biospace.com/news_story.aspx?StoryID=286743&full=1
http://www.biospace.com/news_story.aspx?StoryID=286743&full=1
No comments:
Post a Comment